

Interim Report Card: Progress towards Global HBV and HCV Elimination

As we start the last decade to reach our shared 2030 elimination goals, let's celebrate our achievements to 2020 and commit to overcoming our remaining challenges.

Working together, we will achieve elimination.

WHO Hepatitis Elimination Goals

2020

Interim Goals

Key targets:

- >10% reduction in mortality
- <1% HBsAg prevalence among children US
- 90% Hep B 3 dose coverage
- 50% Birth dose coverage
- >200 needles/syringes per PWID

2030

Goals

Key targets:

- >65% reduction in mortality
- <0.1% HBsAg prevalence among children US
- 90% Hep B 3 dose coverage
- 90% Birth dose coverage
- >300 needles/syringes per PWID

Benefits of elimination



26.8 M deaths would be averted; 4.5 M before 2030



Cost-saving or cost-effective investment

Elimination would only cost an additional 1.5% of projected total SDG costs (US\$ 58.7 B)

Source: WHO. Global health sector strategy on viral hepatitis 2016-2021

Source: Tordrup D, et al. Lancet Glob Health. 2019.

Global burden of HBV and HCV

317 M

People living with HBV

(95% CI 283,568,513-350,881,560)

555,487

Number of HBV-related deaths, 2019

(95% CI 487,100-630,128)

112 M

People living with HCV

(95% CI 90,504,160-137,694,467)

542,316

Number of HCV-related deaths, 2019

(95% CI 476,714-608,894)


40%

of liver cancer deaths due to HBV

29%


of liver cancer deaths due to HCV

Global HBV-related deaths 1990, 2000, 2015, and 2019




Source: IHME, 2020

Global HCV-related deaths 1990, 2000, 2015, and 2019




Source: IHME, 2020

20 Countries with Largest Burden of HBV-related Deaths represent 81% of Global Deaths



Source: IHME, 2020


20 Countries with Largest Burden of HCV-related Deaths Represent 76% of Global Deaths



Source: IHME, 2020


Regional progress on Health Impact Targets

Percent of countries with ≥10% HBV mortality decline 2015-2019




Source: IHME, 2020
Based on HBV-related mortality rate or mortality count

Percent of countries with ≥10% HCV mortality decline 2015-2019



Source: IHME, 2020
Based on HBV-related mortality rate or mortality count


Percent of countries with < 1% HBsAg prevalence among children ≤ 5 years



Source: IHME, 2020


Regional Progress on Service Delivery Targets

Percent of countries with > 90% infant HepB 3 dose vaccine coverage




Source: CGHE Dashboards via WHO/UNICEF, 2018

Percent of countries with > 50% birth dose HepB vaccine coverage



Source: CGHE Dashboards via WHO/UNICEF, 2018

Percent of countries with > 200 syringe exchanges/ drug user/yr



Source: CGHE Dashboards via Larney et al 2017, ECDC, and other sources

Regional Progress on Key Policy Indicators



National Action Plan



> 1 NSP program



> 1 OST program



Access to HBV generics



Access to HCV generics

	National Action Plan	> 1 NSP program	> 1 OST program	Access to HBV generics	Access to HCV generics
AFRO	11% (5)	17% (8)	13% (6)	96% (44)	98% (45)
EMRO	10% (2)	33% (7)	24% (5)	33% (7)	67% (14)
EURO	32% (17)	89% (47)	87% (46)	15% (8)	34% (18)
PAHO	46% (16)	14% (5)	17% (6)	63% (22)	80% (28)
SEARO	27% (3)	55% (6)	64% (7)	91% (10)	100% (11)
WPRO	15% (4)	26% (7)	22% (6)	52% (14)	74% (20)
Global	26% (50)	41% (80)	39% (76)	54% (105)	70% (136)

Source: CGHE Dashboards via CGHE Action Plan Evidence Base; Harm Reduction International, 2019; Medicines Patent Pool

Costs of Testing and Treatment in Low- and Middle-Income Countries Remains Variable

Rapid HCV diagnostic testing	HCV PCR
\$0.30-\$2.10	\$9-\$70
HBV treatment	HCV treatment
\$32	\$28-\$1,347
Per year for tenofovir	For 12 weeks of therapy

Sources: CHAI HCV Market Intelligence Report; 2020; WHO

Explore the country dashboards at <https://www.globalhep.org/country-profiles> and send us your thoughts on progress towards elimination at globalhep@taskforce.org